Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT

Bone Marrow Transplantation volume 43, pages 539–545 (2009)Cite this article

Abstract

Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients. We investigated 348 MM patients undergoing high-dose melphalan treatment followed by Auto-SCT and examined the influence of single nucleotide polymorphisms (SNPs) in genes involved in the inflammatory response. We found that the polymorphism IL-1β T-31C significantly influenced overall survival (OS; P=0.02) and that carriers of the variant C-allele had a significantly longer survival than homozygous wild-type allele TT-carriers (relative risk 0.6 (95% CI=0.5–0.9); P=0.008). The polymorphisms IL-6 G-174C, IL-10 C592A, PPARγ2 Pro12Ala, COX-2 A-1195G, COX-2 T8473C and NFKB1 ins/del did not influence the OS in this group of patients. Furthermore, homozygous carriers of the variant allele of IL-1β T-31C were at 1.37-fold (CI=1.05–1.80) increased risk of MM as compared with population-based controls (P=0.02). Our results indicate that IL-1β is involved in the pathogenesis of MM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bonizzi G, Karin M . The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280–288.

    Article  CAS  PubMed  Google Scholar 

  2. Naugler WE, Karin M . NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18: 19–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ray DM, Bernstein SH, Phipps RP . Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 2004; 113: 203–213.

    Article  CAS  PubMed  Google Scholar 

  4. El Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398–402.

    Article  CAS  PubMed  Google Scholar 

  5. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003; 63: 3560–3566.

    CAS  PubMed  Google Scholar 

  6. Howell WM, Rose-Zerilli MJ . Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006; 5: 143–149.

    Article  CAS  PubMed  Google Scholar 

  7. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27–38.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565–576.

    CAS  PubMed  Google Scholar 

  9. Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen P et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007; 120: 1036–1045.

    Article  CAS  PubMed  Google Scholar 

  10. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  11. Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006; 133: 389–396.

    Article  PubMed  Google Scholar 

  12. Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G et al. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer 2008; 112: 129–135.

    Article  CAS  PubMed  Google Scholar 

  13. Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H et al. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 2007; 624: 88–100.

    Article  CAS  PubMed  Google Scholar 

  14. Miller SA, Dykes DD, Polesky HF . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Saber AT, Nielsen LR, Dictor M, Hagmar L, Mikoczy Z, Wallin H . K-ras mutations in sinonasal adenocarcinomas in patients occupationally exposed to wood or leather dust. Cancer Lett 1998; 126: 59–65.

    Article  CAS  PubMed  Google Scholar 

  16. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A . Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007; 617: 138–146.

    Article  CAS  PubMed  Google Scholar 

  17. Li ZW, Dalton WS . Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006; 20: 333–342.

    Article  PubMed  Google Scholar 

  18. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B . Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 1998; 103: 1152–1160.

    Article  CAS  PubMed  Google Scholar 

  19. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA . Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93: 300–305.

    CAS  PubMed  Google Scholar 

  20. Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 2006; 26: 83–95.

    Article  CAS  PubMed  Google Scholar 

  21. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002; 123: 1793–1803.

    Article  CAS  PubMed  Google Scholar 

  22. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 2006; 15: 519–529.

    Article  CAS  PubMed  Google Scholar 

  23. Lind H, Haugen A, Zienolddiny S . Differential binding of proteins to the IL1B-31 T/C polymorphism in lung epithelial cells. Cytokine 2007; 38: 43–48.

    Article  CAS  PubMed  Google Scholar 

  24. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F . Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942–949.

    Article  CAS  PubMed  Google Scholar 

  25. Nakahara T, Urabe K, Fukagawa S, Uchi H, Inaba K, Furue M et al. Engagement of human monocyte-derived dendritic cells into interleukin (IL)-12 producers by IL-1beta+interferon (IFN)-gamma. Clin Exp Immunol 2005; 139: 476–482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Motta MR, Castellani S, Rizzi S, Curti A, Gubinelli F, Fogli M et al. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003; 121: 240–250.

    Article  PubMed  Google Scholar 

  27. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, Kuliczkowski K et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 2005; 96: 241–246.

    Article  CAS  PubMed  Google Scholar 

  28. Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000; 109: 39–45.

    Article  CAS  PubMed  Google Scholar 

  29. Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11: 5504–5514.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the following grants: Kong Christian den Tiendes fond, the research fund at Herlev Hospital. Participants of NMSG. Christina Køgs Andersen.

Author information

Authors and Affiliations

  1. Department of Oncology and Hematology, Roskilde County Hospital, Roskilde, Denmark

    A J Vangsted

  2. Department of Hematology, University of Copenhagen at Herlev, Herlev, Denmark

    A J Vangsted, T W Klausen & A O Gang

  3. National Research Center for the Working Environment, Copenhagen, Denmark

    W Ruminski & U Vogel

  4. Department of Hematology, University Hospital of Copenhagen at Rigshospitalet, Copenhagen, Denmark

    P Gimsing

  5. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

    N F Andersen & J L Nielsen

  6. Department of Hematology, Odense University Hospital, Odense, Denmark

    N Abildgaard & L M Knudsen

  7. Department of Hematology, Aalborg University Hospital, Aalborg, Denmark

    H Gregersen

  8. Department for Toxicology and Risk Assessment, National Food Institute, Technical University of Denmark, Copenhagen, Denmark

    U Vogel

  9. Institute for Science, Systems and Models, Roskilde University, Roskilde, Denmark

    U Vogel

Authors
  1. A J Vangsted
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T W Klausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Ruminski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Gimsing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N F Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A O Gang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Abildgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L M Knudsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J L Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Gregersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. U Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A J Vangsted.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vangsted, A., Klausen, T., Ruminski, W. et al. The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 43, 539–545 (2009). https://doi.org/10.1038/bmt.2008.351

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.351

Keywords

This article is cited by

Search

Advanced search

Quick links